|
Rhythm Pharmaceuticals, Inc. (RYTM) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Rhythm Pharmaceuticals, Inc. (RYTM) Bundle
¡Simplifique la valoración de Rhythm Pharmaceuticals, Inc. (RYTM) con esta calculadora DCF personalizable! Con Real Rhythm Pharmaceuticals, Inc. (RYTM) Financials y entradas de pronóstico ajustable, puede probar escenarios y descubrir Rhythm Pharmaceuticals, Inc. (RYTM) valor razonable en minutos.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | 3.2 | 23.6 | 77.4 | 116.1 | 174.2 | 261.3 | 392.0 | 588.0 |
| Revenue Growth, % | 0 | 0 | 0 | 649.46 | 227.56 | 50 | 50 | 50 | 50 | 50 |
| EBITDA | -145.2 | -135.9 | -68.5 | -174.5 | -168.5 | -23.2 | -34.8 | -52.3 | -78.4 | -117.6 |
| EBITDA, % | 100 | 100 | -2170.39 | -738.28 | -217.58 | -20 | -20 | -20 | -20 | -20 |
| Depreciation | .8 | .7 | 1.2 | 1.4 | 1.8 | 56.9 | 85.3 | 128.0 | 192.0 | 288.0 |
| Depreciation, % | 100 | 100 | 36.72 | 5.94 | 2.27 | 48.98 | 48.98 | 48.98 | 48.98 | 48.98 |
| EBIT | -146.0 | -136.6 | -69.6 | -175.9 | -170.2 | -23.2 | -34.8 | -52.3 | -78.4 | -117.6 |
| EBIT, % | 100 | 100 | -2207.1 | -744.22 | -219.85 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | 292.5 | 172.8 | 294.9 | 333.3 | 275.8 | 116.1 | 174.2 | 261.3 | 392.0 | 588.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | 1.0 | 6.2 | 14.9 | 64.6 | 96.9 | 145.3 | 218.0 | 326.9 |
| Account Receivables, % | 100 | 100 | 32.5 | 26.33 | 19.2 | 55.61 | 55.61 | 55.61 | 55.61 | 55.61 |
| Inventories | .0 | .0 | .1 | 2.9 | 8.6 | 52.7 | 79.1 | 118.6 | 178.0 | 266.9 |
| Inventories, % | 100 | 100 | 3.52 | 12.34 | 11.14 | 45.4 | 45.4 | 45.4 | 45.4 | 45.4 |
| Accounts Payable | 10.4 | 4.9 | 5.7 | 4.8 | 4.9 | 75.9 | 113.8 | 170.7 | 256.0 | 384.1 |
| Accounts Payable, % | 100 | 100 | 181.9 | 20.29 | 6.31 | 65.32 | 65.32 | 65.32 | 65.32 | 65.32 |
| Capital Expenditure | -3.4 | -.2 | -5.4 | -4.3 | .0 | -27.4 | -41.2 | -61.8 | -92.6 | -139.0 |
| Capital Expenditure, % | 100 | 100 | -172.29 | -18.11 | -0.06070155 | -23.63 | -23.63 | -23.63 | -23.63 | -23.63 |
| Tax Rate, % | -0.30633 | -0.30633 | -0.30633 | -0.30633 | -0.30633 | -0.30633 | -0.30633 | -0.30633 | -0.30633 | -0.30633 |
| EBITAT | -139.7 | -133.2 | -68.0 | -177.8 | -170.7 | -22.8 | -34.2 | -51.3 | -77.0 | -115.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -131.8 | -138.3 | -72.6 | -189.6 | -183.3 | -16.2 | -10.8 | -16.2 | -24.2 | -36.3 |
| WACC, % | 14.74 | 14.75 | 14.75 | 14.76 | 14.76 | 14.75 | 14.75 | 14.75 | 14.75 | 14.75 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -65.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -37 | |||||||||
| Terminal Value | -291 | |||||||||
| Present Terminal Value | -146 | |||||||||
| Enterprise Value | -211 | |||||||||
| Net Debt | -59 | |||||||||
| Equity Value | -153 | |||||||||
| Diluted Shares Outstanding, MM | 58 | |||||||||
| Equity Value Per Share | -2.65 |
What You Will Get
- Comprehensive RYTM Financials: Access to historical and projected data for precise valuation.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Real-Time Calculations: Dynamic calculations for intrinsic value and NPV.
- Scenario Testing: Evaluate various scenarios to assess Rhythm Pharmaceuticals' future outlook.
- User-Friendly Interface: Designed for professionals but easy for newcomers to navigate.
Key Features
- Comprehensive Historical Data: Rhythm Pharmaceuticals' financial statements and pre-filled projections.
- Customizable Variables: Adjust WACC, tax rates, revenue growth, and EBITDA margins to fit your analysis.
- Real-Time Valuation: Instantly view Rhythm Pharmaceuticals' intrinsic value as calculations update live.
- Insightful Visualizations: Interactive dashboard charts illustrate valuation outcomes and essential metrics.
- Designed for Precision: A reliable tool tailored for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the Excel file for Rhythm Pharmaceuticals, Inc. (RYTM).
- Step 2: Review the pre-filled financial data and forecasts specific to Rhythm Pharmaceuticals.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the results for informed investment decisions.
Why Choose This Calculator?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters effortlessly to suit your analysis needs.
- Real-Time Feedback: Observe immediate updates to Rhythm Pharmaceuticals’ valuation as you tweak the inputs.
- Preloaded Data: Comes equipped with Rhythm Pharmaceuticals’ actual financial metrics for swift evaluations.
- Preferred by Experts: Utilized by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Healthcare Professionals: Understand the valuation of biopharmaceutical companies and apply it to real-world scenarios.
- Researchers: Utilize advanced models in studies related to drug development and market strategies.
- Investors: Evaluate your investment strategies and analyze the market performance of Rhythm Pharmaceuticals (RYTM).
- Financial Analysts: Enhance your analysis with a customizable DCF model specifically designed for biotech firms.
- Entrepreneurs: Learn from the valuation processes of established biopharmaceutical companies like Rhythm Pharmaceuticals (RYTM).
What the Template Contains
- Historical Data: Includes Rhythm Pharmaceuticals' past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Rhythm Pharmaceuticals' intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Rhythm Pharmaceuticals' financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.